Enhanced Whole Genome Sequencing Will Open New Global Markets

Key Takeaways

• Broadened clinical endorsements, new service launches, and international certifications strengthen market position, drive revenue growth, and diversify global reach.
  
• Operational efficiencies and expanded managed care contracts boost volume growth, enhance gross margins, and establish a sustainable foundation for future profitability.
  
• High spending and reliance on early-stage therapies raise earnings risk, while organic margin growth and global expansion face significant execution and market uncertainties.

Catalysts

Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

• The recent endorsement by major medical societies (e.g., American Academy of Pediatrics, National Society of Genetic Counselors, and American College of Medical Genetics and Genomics) recommending genome/exome sequencing as a first-tier test significantly broadens the potential user base, likely driving increased test volumes and top-line revenue growth over coming years.
  
• Launch of an enhanced whole genome sequencing service (including PCR-free NGS and integrated RNA analysis) provides greater clinical utility and differentiation, supporting expansion into new clinical indications and markets, which should lead to incremental revenue streams and higher market share.
  
• Achieving CE Mark certification for the Fulgent exome and analytical software in Europe positions the company to grow internationally, capturing additional revenue and diversifying geographic exposure beyond the US.
  
• Expanded managed care contracts and national in-network status-already covering over 35 million new lives this year-create a foundation for sustainable volume growth and improved gross margin realization in core testing services.
  
• Ongoing investment in laboratory automation, streamlined operations, and bioinformatics continues to improve operational efficiency, supporting non-GAAP gross margin expansion even as volumes increase.

Fulgent Genetics Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Fulgent Genetics's revenue will grow by 10.5% annually over the next 3 years.
• Analysts are not forecasting that Fulgent Genetics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Fulgent Genetics's profit margin will increase from -16.8% to the average US Healthcare industry of 5.4% in 3 years.
• If Fulgent Genetics's profit margin were to converge on the industry average, you could expect earnings to reach $22.0 million (and earnings per share of $0.73) by about September 2028, up from $-51.0 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 42.0x on those 2028 earnings, up from -13.2x today. This future PE is greater than the current PE for the US Healthcare industry at 20.9x.
• Analysts expect the number of shares outstanding to grow by 0.07% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Fulgent Genetics Future Earnings Per Share Growth

Risks

• Heavy and accelerating investments in R&D, sales, and marketing are resulting in ongoing operating losses and negative operating margins (guidance: non-GAAP operating margin of -13% for 2025, GAAP EPS loss forecast), which may lead to sustained or increasing cash burn and continued pressure on net earnings despite top-line growth.
  
• Long-term contraction in COVID-19 testing revenue has made the company highly reliant on its core lab services and emerging therapeutic pipeline, exposing Fulgent to heightened business risk and the possibility of revenue volatility or slowdowns if market competition or reimbursement trends shift unfavorably.
  
• The therapeutic development pipeline (FID-007, FID-022) remains in early clinical stages (Phase I/II), requiring multi-year investments and subject to high clinical, regulatory, and commercialization risk, with no near-term likelihood of significant revenue, increasing the risk of delayed return and further impacting earnings and margins.
  
• The company's margin improvements in the most recent quarter were partly due to one-time accounting adjustments, suggesting that organic, sustainable margin expansion may be less robust than reported, possibly limiting future margin upside and affecting bottom-line profitability.
  
• Global expansion initiatives, including reliance on new sales hires in uncovered geographies and international (CE Mark) market entry, increase execution risk and may face competitive pressures, slower-than-expected uptake, or unforeseen regulatory/reimbursement challenges, which could dampen revenue growth and pressure net margins.

Valuation

• The analysts have a consensus price target of $25.333 for Fulgent Genetics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $21.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $408.6 million, earnings will come to $22.0 million, and it would be trading on a PE ratio of 42.0x, assuming you use a discount rate of 6.8%.
• Given the current share price of $22.02, the analyst price target of $25.33 is 13.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.